Form 8-K - Current report:
SEC Accession No. 0001493152-26-036383
Filing Date
2026-08-06
Accepted
2026-08-06 17:00:22
Documents
13
Period of Report
2026-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 40010
2 EX-10.1 ex10-1.htm EX-10.1 268782
3 EX-10.2 ex10-2.htm EX-10.2 103113
  Complete submission text file 0001493152-26-036383.txt   652399

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20260731.xsd EX-101.SCH 3026
5 XBRL LABEL FILE prph-20260731_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE prph-20260731_pre.xml EX-101.PRE 22366
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3136
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 261250200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)